Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
| Autor: | Von Hoff Dd, Erkut Borazanci |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Paclitaxel Combination therapy FOLFIRINOX Antineoplastic Agents Adenocarcinoma Deoxycytidine Albumins Internal medicine Pancreatic cancer Product Surveillance Postmarketing medicine Humans Neoplasm Invasiveness Survival rate Hepatology business.industry Gastroenterology Cancer medicine.disease Gemcitabine Pancreatic Neoplasms Survival Rate Treatment Outcome medicine.anatomical_structure Clinical Trials Phase III as Topic Drug Therapy Combination Pancreas business medicine.drug |
| Zdroj: | Expert Review of Gastroenterology & Hepatology. 8:739-747 |
| ISSN: | 1747-4132 1747-4124 |
| Popis: | Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer of poor prognosis with a high mortality, particularly in the advanced or metastatic setting. Until 2011 and the Phase III results of FOLFIRINOX, standard treatment options were limited to gemcitabine. Combination therapy had shown either a lack of or very limited improvement versus monotherapy with gemcitabine. With the positive results of the MPACT study in 2013 showing improved survival with nab-paclitaxel plus gemcitabine combination therapy, there are now more options for oncologists to treat patients with advanced pancreatic cancer. This paper will highlight the Phase I/II and Phase III trials of nab-paclitaxel plus gemcitabine along with discussing their biology and further possible development in treating patients with pancreatic cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|